Authorized purpose: Semi-automatic segmentation, labeling, and volumetric quantification of known WHO grade 4 glioblastoma in adults aged 18 years or older using T1 post-contrast or FLAIR MRI.
Clinical role
AI-assisted contouring and volumetric measurement aid; the AI supplies an initial contour for trained-professional review and manual revision, with prior-scan comparison and reporting, and is not a detection or diagnosis tool.
Images and patients
MRI · Brain and glioblastoma
Key limitation
Keep in mind: The device is not for primary diagnosis, tumor detection, or use as the sole diagnostic metric, and is not intended for brain tumor types other than grade 4 glioblastoma. A trained professional must review and complete the contours; the packet does not establish use for other sequences or populations.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Semi-automatic segmentation, labeling, and volumetric quantification of known WHO grade 4 glioblastoma in adults aged 18 years or older using T1 post-contrast or FLAIR MRI.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain and glioblastoma Input: DICOM MRI in 2D or 3D using either T1 post-contrast (T1c) or FLAIR sequences from male or female patients aged 18 years or older with pathologically proven WHO grade 4 glioblastoma.
Who uses it?Intended users: Trained medical professionals, including board-certified neuroradiologists; professional review, manual completion, and approval are required.
What does the software produce?Output: Segmentation contours and volumes for tumor, edema, and necrosis subcomponents in FLAIR and enhancing and necrosis subcomponents in T1c, comparison with prior scans when available, and a PDF report.
What is its most important limitation?Key limitation: The device is not for primary diagnosis, tumor detection, or use as the sole diagnostic metric, and is not intended for brain tumor types other than grade 4 glioblastoma. A trained professional must review and complete the contours; the packet does not establish use for other sequences or populations.
Clinical takeaway. Clinical role: Semi-automatic segmentation, labeling, and volumetric quantification of known WHO grade 4 glioblastoma in adults aged 18 years or older using T1 post-contrast or FLAIR MRI.
Evidence takeaway. Evidence from the reviewed source record: FDA performance testing compared AI contours with manual contours by three U.S. board-certified neuroradiologists on 46 pre- and post-operative MRIs from 19 U.S. centers. T1c mean overall DSC was 0.95 (95% CI 93%-96%); true-positive T1c mean DSC was 83%, with sensitivity 92.7% and specificity 97.2%. FLAIR mean overall DSC was 92% (95% CI 90%-94%); true-positive FLAIR mean DSC was 80%, with median sensitivity 93.4% and specificity 98.6%. The proportions of DSC measurements exceeding the 0.88 threshold were 85% for FLAIR (95% CI 72%-92%) and 93% for T1c (95% CI 82%-98%), both p<0.001.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Semi-automatic segmentation, labeling, and volumetric quantification of known WHO grade 4 glioblastoma in adults aged 18 years or older using T1 post-contrast or FLAIR MRI.
AI-assisted contouring and volumetric measurement aid; the AI supplies an initial contour for trained-professional review and manual revision, with prior-scan comparison and reporting, and is not a detection or diagnosis tool.
DICOM MRI in 2D or 3D using either T1 post-contrast (T1c) or FLAIR sequences from male or female patients aged 18 years or older with pathologically proven WHO grade 4 glioblastoma.
Segmentation contours and volumes for tumor, edema, and necrosis subcomponents in FLAIR and enhancing and necrosis subcomponents in T1c, comparison with prior scans when available, and a PDF report.
The device is not for primary diagnosis, tumor detection, or use as the sole diagnostic metric, and is not intended for brain tumor types other than grade 4 glioblastoma. A trained professional must review and complete the contours; the packet does not establish use for other sequences or populations.
FDA performance testing compared AI contours with manual contours by three U.S. board-certified neuroradiologists on 46 pre- and post-operative MRIs from 19 U.S. centers. T1c mean overall DSC was 0.95 (95% CI 93%-96%); true-positive T1c mean DSC was 83%, with sensitivity 92.7% and specificity 97.2%. FLAIR mean overall DSC was 92% (95% CI 90%-94%); true-positive FLAIR mean DSC was 80%, with median sensitivity 93.4% and specificity 98.6%. The proportions of DSC measurements exceeding the 0.88 threshold were 85% for FLAIR (95% CI 72%-92%) and 93% for T1c (95% CI 82%-98%), both p<0.001.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA performance testing compared AI contours with manual contours by three U.S. board-certified neuroradiologists on 46 pre- and post-operative MRIs from 19 U.S. centers. T1c mean overall DSC was 0.95 (95% CI 93%-96%); true-positive T1c mean DSC was 83%, with sensitivity 92.7% and specificity 97.2%. FLAIR mean overall DSC was 92% (95% CI 90%-94%); true-positive FLAIR mean DSC was 80%, with median sensitivity 93.4% and specificity 98.6%. The proportions of DSC measurements exceeding the 0.88 threshold were 85% for FLAIR (95% CI 72%-92%) and 93% for T1c (95% CI 82%-98%), both p<0.001.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
i2Contour regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K233822
Samplen=33
IndependenceIndependence not established
K233822
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233822. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM MRI in 2D or 3D using either T1 post-contrast (T1c) or FLAIR sequences from male or female patients aged 18 years or older with pathologically proven WHO grade 4 glioblastoma.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Web-based software with DICOM MRI input and PDF report output; exact hosting, PACS/RIS/EHR interfaces, versions, and local compatibility are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes i2Contour as a web-based software platform that combines AI with a user interface for review, manual contouring, and approval. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The MRIMath i2Contour is a web-based software platform designed for the contouring and segmentation of the T1c and FLAIR sequences" … "It combines AI with a user interface (UI) for review, manual contouring, and approval.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Segmentation contours and volumes for tumor, edema, and necrosis subcomponents in FLAIR and enhancing and necrosis subcomponents in T1c, comparison with prior scans when available, and a PDF report.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Segmentation contours and volumes for tumor, edema, and necrosis subcomponents in FLAIR and enhancing and necrosis subcomponents in T1c, comparison with prior scans when available, and a PDF report.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes i2Contour as a web-based software platform that combines AI with a user interface for review, manual contouring, and approval. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The MRIMath i2Contour is a web-based software platform designed for the contouring and segmentation of the T1c and FLAIR sequences" … "It combines AI with a user interface (UI) for review, manual contouring, and approval.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Web-based software with DICOM MRI input and PDF report output; exact hosting, PACS/RIS/EHR interfaces, versions, and local compatibility are not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K233822 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Post-process previously acquired cervical-spine MR images to segment vertebrae and disks, calculate quantitative measurements, label out-of-range values, and export results for user review and interpretation.
Modality
MRI
Anatomy
Cervical spine: vertebrae C3-C7 and disks C2C3 through C7T1
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.